Use of Calcium Channel Blockers and Risk of Active Tuberculosis Disease

Calcium channel blockers (CCBs) are known to reduce the availability of iron—an important mineral for intracellular pathogens. Nonetheless, whether use CCBs modifies risk active tuberculosis in clinical setting remains unclear. To determine may modify disease, we conducted a nested case-control study using National Health Insurance Research Database Taiwan between January 1999 and December 2011. Conditional logistic regression disease score adjustment were used calculate associated with CCB use. Subgroup analyses investigated effect different types potential modification subpopulations. A total 8164 new cases 816 400 controls examined. Use was 32% decrease (relative [RR], 0.68 [95% CI, 0.58–0.78]) after score. Compared nonuse CCBs, dihydropyridine lower (RR, 0.63 0.53–0.79]) than nondihydropyridine 0.73 0.57–0.94]). In contrast, ?-blockers 0.99 0.83–1.12]) or loop diuretics 0.88 0.62–1.26]) not tuberculosis. subgroup analyses, similar among patients heart failure cerebrovascular diseases. Our confirms that decreases